Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/COC.0000000000000253 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Aurora kinase A drives non-canonical YAP1/TAZ crosstalk to sustain primary resistance to anti-EGFR therapies in colorectal cancer.
Mol Ther Oncol
September 2025
Translational Oncology Division, Oncohealth Institute, IIS - Fundación Jiménez Díaz University Hospital (IIS-FJD, UAM), Madrid, Spain.
Anti-epidermal growth factor receptor (EGFR) therapies are the most recommended first-line treatment for wild-type unresectable metastatic colorectal cancer (CRC) according to the European Society for Medical Oncology guidelines. However, primary resistance renders this treatment ineffective for almost 40% of patients. Our previous work identified Aurora kinase A (AURKA) as a key resistance driver through non-canonical, Hippo-independent Yes-associated protein 1 (YAP1) activation.
View Article and Find Full Text PDFEffectiveness of oxaliplatin-based second-line therapy following cetuximab+FOLFIRI or bevacizumab+FOLFIRI in KRAS wild-type metastatic colorectal cancer without primary tumor resection.
Ann Coloproctol
August 2025
Division of Colorectal Surgery, Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
Purpose: Wild-type unresectable metastatic colorectal cancer (mCRC) poses challenges for treatment optimization. Effective first-line targeted therapies are crucial for improving outcomes, particularly when combined with second-line oxaliplatin-based chemotherapies. This study examined the effects of first-line cetuximab+FOLFIRI versus bevacizumab+FOLFIRI, followed by second-line oxaliplatin-based chemotherapy, on survival among patients with KRAS wild-type mCRC without primary tumor resection (PTR).
View Article and Find Full Text PDFCost-Utility Analysis Alongside the GORTEC 2014-01 TPExtreme trial: TPEx versus EXTREME as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma.
Value Health
August 2025
Biostatistics and Epidemiology Unit, Gustave Roussy, Oncostat 1018 INSERM, labeled Ligue Contre le Cancer, University Paris-Saclay, Villejuif, France.
Objectives: The randomized GORTEC 2014-01 TPExtreme trial showed no significant improvement in overall survival with TPEx chemotherapy regimen (docetaxel-platinum-cetuximab) versus EXTREME regimen (platinum-fluorouracil-cetuximab) in first line treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). However, the TPEx regimen had a favorable safety profile, and could provide an alternative to standard of care with the EXTREME regimen in this setting. Our aim was to assess the cost-utility of the TPEx strategy versus EXTREME strategy in the French setting.
View Article and Find Full Text PDFEfficacy and safety of first-line cetuximab therapy for older patients (aged ≥ 70 years) with wild-type metastatic colorectal cancer: a nationwide real-world study.
Am J Cancer Res
July 2025
Division of Colorectal Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University Kaohsiung 80708, Taiwan.
This study investigated the efficacy and safety of first-line cetuximab-based chemotherapy for patients aged 70 years and older with wild-type metastatic colorectal cancer (mCRC) from nationwide registry data in Taiwan. The study included 756 patients with wild-type mCRC who received cetuximab and chemotherapy as first-line therapy at multiple institutions in Taiwan from November 2016 to January 2021. After the prognoses of two age groups (≥ 70 and < 70 years) were determined, progression-free survival (PFS) and cancer-specific survival (CSS) were regarded as the primary endpoints and severe adverse events (SAEs) were also compared.
View Article and Find Full Text PDFOutcomes for FOLFIRI plus bevacizumab or cetuximab in patients treated with oxaliplatin-based adjuvant therapy: A combined analysis of FIRE-3 and CALGB/SWOG 80405 (Alliance).
Eur J Cancer
September 2025
Department of Medicine III and Comprehensive Cancer Center (CCC Munich LMU), University Hospital, LMU Munich, Munich, Germany.
Background: Metastatic recurrence of colorectal cancer (mCRC) after adjuvant therapy may differ biologically from recurrence in untreated mCRC. We examined first-line treatment outcomes of patients within the phase III CALGB/SWOG 80405 (CALGB 80405) and FIRE-3 trials according to previous exposure to oxaliplatin-based adjuvant treatment.
Methods: Patients from CALGB 80405 primary analysis (N = 1131) and FIRE-3 intent-to-treat population (N = 592) treated with FOLFIRI who previously received either oxaliplatin-based adjuvant therapy or no adjuvant therapy were identified.